NDAC
This article was originally published in The Tan Sheet
Executive Summary
Meeting tentatively scheduled for April 22-23, according to Jan. 3 Federal Register notice listing FDA advisory committee dates in 2002. NDAC, which last met in May 2001 to consider switching second-generation antihistamines, may be asked to revisit OTC suitability of cholesterol-lowering statin drugs; in July 2000, committee voted against switching Pravachol (Bristol-Myers Squibb), Mevacor (Merck). FDA's TSE committee is slated to meet Jan. 16-17, June 26-27, Oct. 17-18; Food Advisory Committee is scheduled to meet June 4-5, Sept. 24-25...